Exact’s BLUE-C top-line data beat expectations, says William Blair

William Blair analyst Andrew Brackmann noted that Exact Sciences announced top-line results from its 20,000-plus participant pivotal BLUE-C study designed to evaluate performance of next-generation Cologuard ahead of its investor day on Wednesday, telling investors that the results were “impressive and met or exceeded goals set by management in recent meetings,” as well as the performance bars it sees being set by investors. The firm, which noted that the test showed improvement in “every top-line metric” compared to the FDA registrational trial for Cologuard 1.0 as well as “a major reduction” in the false positives rate, has an Outperform rating on Exact Sciences shares.